AbCellera reports Q2 EPS (12c), consensus (16c)

Reports Q2 revenue $17.1M, consensus $6.4M. “In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575. I am pleased to announce today that we have successfully begun dosing the first participants in the Phase 1 study of ABCL635. This is a landmark achievement for AbCellera (ABCL), one that completes our transition to a clinical-stage biotechnology company,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Today we also announced that a third program, ABCL688, has advanced into IND-enabling studies. With over $750 million in available liquidity, we are well-positioned to continue to execute our strategy.”